The podcaster Andrew Huberman has called retatrutide the trillion-dollar drug thats going to change everything. So much has changed already
Users have experienced less hot flashes, more energy and improved moods
The Right Mindset Going In Approach the first session as a calm, one time learning curve rather than a test you might fail
Broad Application in Cardiovascular Concerns: Major Potential In 2025, crucial research activities will be developing new applications of GLP-1 receptor agonists in heart conditions, including protective effects on the heart and blood vessels, probably decreasing the risk of heart attack, stroke, and other cardiovascular events
(But as the review points out, some research is conflicting.) Exactly whats going on needs further study
As part of the prior authorization process for Bridge, prescribing clinicians will need to attest that the GLP-1 prescription is for weight reduction and weight management and that beneficiaries meet the clinical criteria and do not have a diagnosis of type 2 diabetes, OSA, or MASH that would make them eligible for GLP-1 coverage under Part D
